Literature DB >> 8114747

Mutant cell lines unresponsive to alpha/beta and gamma interferon are defective in tyrosine phosphorylation of ISGF-3 alpha components.

J E Loh1, C Schindler, A Ziemiecki, A G Harpur, A F Wilks, R A Flavell.   

Abstract

The 84-, 91-, and 113-kDa proteins of the ISGF-3 alpha complex are phosphorylated on tyrosine residues upon alpha interferon (IFN-alpha) treatment and subsequently translocate to the nucleus together with a 48-kDa subunit. In this study, we investigated the presence and the functional status of ISGF-3 alpha subunits and Tyk-2 and JAK1 tyrosine kinases in mutant HeLa cells defective in the IFN-alpha/beta and -gamma response. Stable cell fusion analysis revealed a single complementation group among one class (class B) of mutants. The class B mutants contain detectable level of mRNA and proteins of the 84-, 91-, and 113-kDa proteins, but neither the protein nor mRNA is inducible by IFN-alpha or -gamma. The 91-kDa protein IFN-gamma-activated factor fails to be activated into a DNA-binding state after IFN-alpha or -gamma treatment. In addition, the 91-kDa protein is unable to localize in the nucleus after IFN-alpha and -gamma treatment, and the 113-kDa protein fails to translocate after IFN-alpha treatment. Immunoprecipitation studies document a failure of phosphorylation of the 84- or 91-kDa proteins after IFN-alpha or -gamma treatment. Similarly, no tyrosine-phosphorylated 113-kDa protein was detected after IFN-alpha treatment. The inability of class B mutants to phosphorylate the 84-, 91-, or 113-kDa protein on tyrosine residues correlated with the loss of biological response to IFN-alpha and -gamma. The genetic defect appears to be the absence of the tyrosine kinase JAK1. Our data therefore confirm a recent report that JAK1 plays a critical early signaling role for both IFN-alpha/beta and IFN-gamma systems.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114747      PMCID: PMC358577          DOI: 10.1128/mcb.14.3.2170-2179.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  27 in total

1.  ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains.

Authors:  X Y Fu; D S Kessler; S A Veals; D E Levy; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  A protein tyrosine kinase in the interferon alpha/beta signaling pathway.

Authors:  L Velazquez; M Fellous; G R Stark; S Pellegrini
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

3.  Ouabain-resistant mutants of the rat Na,K-ATPase alpha 2 isoform identified by using an episomal expression vector.

Authors:  V Canfield; J R Emanuel; N Spickofsky; R Levenson; R F Margolskee
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

4.  Activation of the human beta-interferon gene requires an interferon-inducible factor.

Authors:  T Enoch; K Zinn; T Maniatis
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

5.  Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator.

Authors:  D S Kessler; S A Veals; X Y Fu; D E Levy
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

6.  Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins.

Authors:  S A Veals; C Schindler; D Leonard; X Y Fu; R Aebersold; J E Darnell; D E Levy
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

7.  Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro.

Authors:  D E Levy; D S Kessler; R Pine; J E Darnell
Journal:  Genes Dev       Date:  1989-09       Impact factor: 11.361

8.  Transcriptional activation of HLA-DR alpha by interferon gamma requires a trans-acting protein.

Authors:  M A Blanar; E C Boettger; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons.

Authors:  R McKendry; J John; D Flavell; M Müller; I M Kerr; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s).

Authors:  J E Loh; C H Chang; W L Fodor; R A Flavell
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  6 in total

1.  Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis.

Authors:  Y E Chin; M Kitagawa; K Kuida; R A Flavell; X Y Fu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins.

Authors:  M L Vignais; H B Sadowski; D Watling; N C Rogers; M Gilman
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.

Authors:  L F Stancato; M Sakatsume; M David; P Dent; F Dong; E F Petricoin; J J Krolewski; O Silvennoinen; P Saharinen; J Pierce; C J Marshall; T Sturgill; D S Finbloom; A C Larner
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Role of STAT2 in the alpha interferon signaling pathway.

Authors:  S Leung; S A Qureshi; I M Kerr; J E Darnell; G R Stark
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

5.  Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.

Authors:  C H Chang; J D Fontes; M Peterlin; R A Flavell
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

6.  Class II transactivator regulates the expression of multiple genes involved in antigen presentation.

Authors:  C H Chang; R A Flavell
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.